Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000972325
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
6/07/2026
Date registered
Help: Date registered
7/08/2026
Date last updated
Help: Date last updated
7/08/2026
Date data sharing statement initially provided
Help: Data sharing statement date
7/08/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Culturally centred contingency management for Maori with harmful methamphetamine use
Scientific title
Effect of culturally centred contingency management on wellbeing and substance use for Maori with harmful methamphetamine use
Additional trial identifiers [1] 317802 0
HRC Ref ID: 24/642
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Substance use disorder 342717 0
Condition category
Condition code
Mental Health 338853 338853 0 0
Addiction

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Contingency management is a behavioural intervention that uses positive reinforcenment. When someone demonstrates a target behaviour, they are given reinforcers. In this study the target behaviour is abstinence from methamphetamine, verified through a negative urine drug screen (UDS),

The intervention is 12 weeks, with two individual face-to-face visits per week, at a clinic or community partner service. Each visit will take 15 minutes. The visits will be with a clinical psychologist with more than 5 years experience.

At each visit an instant UDS will be administered and tested for methamphetamine. During the visit there will be a brief discussion between the clinical psychologist and participant likely about matters such as; how the participant is managing making changes to their substance use, their circumstances and any social needs, or other topics that the participant wishes to raise.

For negative UDS results (i.e., no presence of methamphetamine) participants will earn positive reinforcers in the form of prize slips that can be used to obtain prizes. For positive UDS results (i.e., presence of methamphetamine) participants will not earn positive reinforcers.

Maori cultural knowledges and practices are integrated throughout to culturally centre the intervention. Foundational to this is recognising that wellbeing for Maori is holistic, encompassing physical, psychological, relational, and spiritual, and in practice this includes creating shared understandings with whaiora through use of Maori health models and measures. In addition, Maori cultural needs will be attended to through working alongside Maori community partners, having Maori clinical psychologists deliver the intervention, including culturally relevant prizes, and use of te reo Maori (Maori language) in intervention materials.

Participants will be provided with a schedule of visits at the commencement of the intervention, which will be updated throughout the 12 weeks. The intervention will be delivered alongside community partner services, who will support engagement. The community partner services provide a variety of existing support including group based therapy and case management, which participants will be able to access in line with their care or treatment plan.
Intervention code [1] 334642 0
Behaviour
Description of the comparator or control
No control group
Control group
Uncontrolled

Outcomes
Primary outcome [1] 346062 0
Methamphetamine use
Timepoint [1] 346062 0
Week 1 through week 12 of intervention, twice per week
Primary outcome [2] 346063 0
Methamphetamine use
Timepoint [2] 346063 0
Baseline, week 6, week 12, 18 weeks post-intervention commencement
Primary outcome [3] 346064 0
Holistic wellbeing
Timepoint [3] 346064 0
Baseline, week 6, week 12, 18 weeks post-intervention commencement
Secondary outcome [1] 464477 0
Substance use
Timepoint [1] 464477 0
Baseline, week 6, week 12, 18 weeks post-intervention commencement
Secondary outcome [2] 465867 0
Experiences of Maori who participate in the intervention
Timepoint [2] 465867 0
Up to 12 weeks post-intervention (13 to 24 weeks post-intervention commencement)

Eligibility
Key inclusion criteria
Participants must: identify as NZ Maori; be 18 years or older; meet criteria for stimunlant use disorder (methamphetamine) (moderate or severe); be engaged with a community partner service; have a goal to stop using methamphetamine, or a goal to trial a period of abstinence from methamphetamine.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
They meet criteria for gambling disorder; or are at imminent or acute risk of harm to themselves or others (as assessed by the referring community partner service or investigator/clinician).

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Not Applicable
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
17/08/2026
Actual
Date of last participant enrolment
Anticipated
1/02/2027
Actual
Date of last data collection
Anticipated
30/07/2027
Actual
Sample size
Target
20
Accrual to date
Final
Recruitment outside Australia
Country [1] 28293 0
New Zealand
State/province [1] 28293 0
Wellington

Funding & Sponsors
Funding source category [1] 322348 0
Government body
Name [1] 322348 0
Health Research Council
Country [1] 322348 0
New Zealand
Primary sponsor type
University
Name
Massey University
Address
Country
New Zealand
Secondary sponsor category [1] 325268 0
None
Name [1] 325268 0
Address [1] 325268 0
Country [1] 325268 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320850 0
Northern B Health and Disability Ethics Committee 
Ethics committee address [1] 320850 0
Ethics committee country [1] 320850 0
New Zealand
Date submitted for ethics approval [1] 320850 0
19/02/2026
Approval date [1] 320850 0
02/06/2026
Ethics approval number [1] 320850 0
2026 FULL 25205

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 151834 0
Dr Eleanor Brittain
Address 151834 0
School of Psychology, Massey University, PO Box 756, Wellington 6140
Country 151834 0
New Zealand
Phone 151834 0
+6449793624
Fax 151834 0
Email 151834 0
[email protected]
Contact person for public queries
Name 151835 0
Eleanor Brittain
Address 151835 0
School of Psychology, Massey University, PO Box 756, Wellington 6140
Country 151835 0
New Zealand
Phone 151835 0
+6449793624
Fax 151835 0
Email 151835 0
[email protected]
Contact person for scientific queries
Name 151836 0
Eleanor Brittain
Address 151836 0
School of Psychology, Massey University, PO Box 756, Wellington 6140
Country 151836 0
New Zealand
Phone 151836 0
+6449793624
Fax 151836 0
Email 151836 0
[email protected]

Data sharing statement
Will the study consider sharing individual participant data?
Yes
Will there be any conditions when requesting access to individual participant data?
Persons/groups eligible to request access:
• Researchers
Conditions for requesting access:
• Yes, conditions apply:
• Requires review on a case-by-case basis by the trial custodian, sponsor or data sharing committee
• Requires approval by an ethics committee
• Requires a data sharing agreement between data requester and trial custodian or sponsor
What individual participant data might be shared?
• De-identified individual participant data:
• All outcomes data
What types of analyses could be done with individual participant data?
• Systematic reviews and meta-analyses
• Studies exploring new research questions
• Health economic analyses
• Studies testing whether findings can be repeated or confirmed
When can requests for individual participant data be made (start and end dates)?
From:
At the end of the study
To:
Not yet decided
Where can requests to access individual participant data be made, or data be obtained directly?
• Email of trial custodian, sponsor or committee: [email protected]

Are there extra considerations when requesting access to individual participant data?
Yes: Maori/Indigenous data sovereignty



What supporting documents are/will be available?

TypeCitationLinkEmailOther DetailsAttachment
Ethical approval    HDEC Letter June 2026.pdf


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.